These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells. Schmidt SM; Schag K; Müller MR; Weck MM; Appel S; Kanz L; Grünebach F; Brossart P Blood; 2003 Jul; 102(2):571-6. PubMed ID: 12576330 [TBL] [Abstract][Full Text] [Related]
12. Identification of C-met oncogene as a broadly expressed tumor-associated antigen recognized by cytotoxic T-lymphocytes. Schag K; Schmidt SM; Müller MR; Weinschenk T; Appel S; Weck MM; Grünebach F; Stevanovic S; Rammensee HG; Brossart P Clin Cancer Res; 2004 Jun; 10(11):3658-66. PubMed ID: 15173072 [TBL] [Abstract][Full Text] [Related]
13. Specific antitumor effects of tumor vaccine produced by autologous dendritic cells transfected with allogeneic osteosarcoma total RNA through electroporation in rats. Yu Z; Sun H; Zhang T; Yang T; Long H; Ma B Cancer Biol Ther; 2009 May; 8(10):973-80. PubMed ID: 19287216 [TBL] [Abstract][Full Text] [Related]
14. CD40-activated B-cell chronic lymphocytic leukemia cells for tumor immunotherapy: stimulation of allogeneic versus autologous T cells generates different types of effector cells. Buhmann R; Nolte A; Westhaus D; Emmerich B; Hallek M Blood; 1999 Mar; 93(6):1992-2002. PubMed ID: 10068672 [TBL] [Abstract][Full Text] [Related]
15. Generation of antigen-presenting cells using cultured dendritic cells and amplified autologous tumor mRNA. Minami K; Yamaguchi Y; Ohshita A; Kawabuchi Y; Ohta K; Hihara J; Toge T Oncology; 2005; 69(5):399-407. PubMed ID: 16319511 [TBL] [Abstract][Full Text] [Related]
16. Autoreactive, cytotoxic T lymphocytes specific for peptides derived from normal B-cell differentiation antigens in healthy individuals and patients with B-cell malignancies. Grube M; Rezvani K; Wiestner A; Fujiwara H; Sconocchia G; Melenhorst JJ; Hensel N; Marti GE; Kwak LW; Wilson W; Barrett JA Clin Cancer Res; 2004 Feb; 10(3):1047-56. PubMed ID: 14871984 [TBL] [Abstract][Full Text] [Related]
17. Induction of myeloma-specific cytotoxic T cells using dendritic cells transfected with tumor-derived RNA. Milazzo C; Reichardt VL; Müller MR; Grünebach F; Brossart P Blood; 2003 Feb; 101(3):977-82. PubMed ID: 12393470 [TBL] [Abstract][Full Text] [Related]
18. An improved protocol for generation of immuno-potent dendritic cells through direct electroporation of CD14+ monocytes. Milano F; van Baal JW; Rygiel AM; Bergman JJ; Van Deventer SJ; Kapsenberg ML; Peppelenbosch MP; Krishnadath KK J Immunol Methods; 2007 Apr; 321(1-2):94-106. PubMed ID: 17336322 [TBL] [Abstract][Full Text] [Related]
19. Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells. Koido S; Hara E; Homma S; Torii A; Toyama Y; Kawahara H; Watanabe M; Yanaga K; Fujise K; Tajiri H; Gong J; Toda G Clin Cancer Res; 2005 Nov; 11(21):7891-900. PubMed ID: 16278414 [TBL] [Abstract][Full Text] [Related]
20. Telomerase (hTERT 611-626) serves as a tumor antigen in B-cell chronic lymphocytic leukemia and generates spontaneously antileukemic, cytotoxic T cells. Kokhaei P; Palma M; Hansson L; Osterborg A; Mellstedt H; Choudhury A Exp Hematol; 2007 Feb; 35(2):297-304. PubMed ID: 17258078 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]